Stock listing

NASDAQ:KARD Kardigan, Inc. Stock

Home listing (NASDAQ) of Kardigan, Inc.

Follow Kardigan, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:KARD

$11.54 USD -0.78 (-6.3%)

Close on Nov 20, 2026

Since Jun 18, 2026 -47.5% · daily closes, Jun 18, 2026 – Nov 20, 2026, adjusted for splits
Day range
$11.49 – $12.77 USDNov 20, 2026
Volume
459,243 sharesNov 20, 2026
Market cap
$1.08B USDAt the close on Nov 20, 2026 · price × 93.60M shares outstanding
Traded on an average day
$9.47M USDMedian day 462,303 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:KARD · Home$11.54 USD-0.78 (-6.3%)459,243$12.09$12.77$11.49$12.32Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KARD · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$11.54-0.78-6.3%$12.09$12.77$11.49459,243
$12.32-0.87-6.6%$13.19$13.51$12.25546,424
$13.19+0.34+2.6%$12.87$13.46$12.65356,746
$12.85-0.97-7.0%$13.63$13.63$12.68395,703
$13.82-0.30-2.1%$13.91$14.36$12.77410,885
$14.12-1.56-9.9%$15.42$15.85$14.11345,772
$15.68+0.50+3.3%$15.35$16.12$15.02432,177
$15.180.000.0%$15.30$15.94$14.93769,733
$15.18-0.34-2.2%$15.50$16.59$15.11421,132
$15.52+1.66+12.0%$14.00$15.56$13.57406,389
$13.86-1.70-10.9%$15.65$15.79$13.74675,632
$15.56+1.24+8.7%$15.24$15.59$14.40491,053
$14.32+0.11+0.8%$14.23$15.19$13.97545,033
$14.21+0.08+0.6%$14.34$14.69$13.53462,303
$14.13-0.18-1.3%$14.25$14.65$13.75452,669
$14.31+0.58+4.2%$14.07$14.94$14.07446,299
$13.73+0.13+1.0%$13.60$13.83$13.21469,173
$13.60+0.97+7.7%$12.65$13.71$12.43452,701
$12.63-0.17-1.3%$12.84$13.15$12.60216,096
$12.80+0.06+0.5%$12.66$12.87$12.34679,813
$12.74-0.11-0.9%$12.86$13.05$12.40380,890
$12.85-0.66-4.9%$13.59$14.01$12.68480,734
$13.51+0.57+4.4%$13.06$13.70$12.74768,714
$12.94-0.09-0.7%$13.04$13.73$12.76622,072
$13.03-0.85-6.1%$13.95$14.51$12.75717,600
$13.88+0.36+2.7%$13.80$14.13$13.13660,900
$13.52+0.55+4.2%$12.53$13.61$12.34826,700
$12.97-1.38-9.6%$14.36$14.61$12.93392,600
$14.35-0.32-2.2%$14.69$15.10$14.21256,800
$14.67+0.47+3.3%$14.44$15.93$14.13740,200
$14.20+0.37+2.7%$13.60$14.47$13.42511,800
$13.83+0.34+2.5%$13.34$14.19$12.231,025,700
$13.49-1.75-11.5%$15.25$15.25$12.521,560,900
$15.24+0.45+3.0%$14.77$15.40$14.35380,900
$14.79+0.54+3.8%$14.48$15.27$14.15524,400
$14.25-0.50-3.4%$14.65$15.13$13.94913,900
$14.75+0.09+0.6%$14.81$14.87$14.16487,800
$14.66-0.12-0.8%$14.75$15.06$14.33493,600
$14.78-0.01-0.1%$14.59$15.25$14.59364,900
$14.79+0.40+2.8%$14.69$15.60$14.07628,900
$14.39-0.13-0.9%$14.54$14.54$13.75862,400
$14.52-1.92-11.7%$16.50$16.50$14.24653,800
$16.44+0.14+0.9%$16.55$16.58$16.08598,200
$16.30-0.34-2.0%$16.86$18.28$16.13724,500
$16.64-0.05-0.3%$16.69$17.00$15.866,566,500
$16.69-0.62-3.6%$17.45$18.48$16.50710,200
$17.31-1.25-6.7%$18.49$19.01$17.15986,900
$18.56-0.49-2.6%$18.95$19.07$18.32344,900
$19.05+0.53+2.9%$18.59$19.39$17.77806,600
$18.52-0.17-0.9%$19.01$19.81$18.41416,400
$18.69-0.99-5.0%$19.85$20.04$18.69433,100
$19.68-1.92-8.9%$21.44$22.00$19.62382,900
$21.60+0.75+3.6%$21.06$22.05$20.77538,100
$20.85+0.11+0.5%$20.50$21.41$20.50279,600
$20.74-1.18-5.4%$21.96$22.22$20.41262,800
$21.92+2.32+11.8%$19.80$22.51$19.74354,900
$19.60-0.56-2.8%$20.05$20.40$19.41327,000
$20.16+0.14+0.7%$20.02$20.72$20.00184,900
$20.02-0.78-3.8%$20.61$20.93$19.99196,600
$20.80-0.38-1.8%$21.12$21.90$20.33546,600
$21.18+0.26+1.2%$20.92$21.47$20.50214,300
$20.92+0.28+1.4%$20.75$21.38$20.51229,955
$20.64-0.38-1.8%$21.04$21.65$20.25281,391
$21.02+0.76+3.8%$20.47$21.76$20.46159,600
$20.26-1.75-8.0%$21.91$22.16$20.01258,400
Ticker
NASDAQ:KARD
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Kardigan, Inc. news

Kardigan, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
7 in the last 12 months · 7 in all · newest Nov 12, 2026 · oldest 2026
Decks
1 deck · latest September 2026

Where Kardigan, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:KARD · Home listing · This pageNASDAQUnited StatesUSD
BOATS:KARDBOATSUnited StatesUSD

Valuation

Price/book 1.9× against a median of 6.1×: 2nd lowest of 11 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$621.1M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Kardigan, Inc. · NASDAQ:KARDUS$1.08BUS$621.1Mn/an/an/a1.9×n/a0.0×n/a
COMPASS Pathways Plc · NASDAQ:CMPSUS$1.14BUS$747.8Mn/an/an/a8.0×n/a0.4×1.65
Ascentage Pharma Group International · HKEX:6855US$1.11BUS$1.14Bn/a13.7×n/a13.4×−216.5%3.8×n/a
Shenzhen Chipscreen Biosciences Co. Ltd. Class A · SSE:688321US$1.10BUS$1.10B102×6.8×n/a2.9×6.6%0.5×n/a
Pharma Mar SA · BME:PHMUS$1.10BUS$978.5M14.6×3.8×16.6×4.2×28.8%0.3×n/a
Alpha Tau Medical Ltd · NASDAQ:DRTSUS$1.09BUS$1.00Bn/an/an/a55.3×n/a0.8×1.89
PYC Therapeutics Limited · ASX:PYCUS$1.07BUS$775.8Mn/an/an/a2.3×n/a0.0×n/a
Jade Biosciences, Inc. · NASDAQ:JBIOUS$1.06BUS$583.6Mn/an/an/a2.3×n/a0.0×1.14
MedinCell SA · EURONEXT:MEDCLUS$1.05BUS$1.02Bn/a38.4×n/a313×−128.9%18.7×n/a
Nektar Therapeutics · NASDAQ:NKTRUS$1.03BUS$492.8Mn/a9.4×n/a1.2×−339.7%0.1×1.28
Mabwell (Shanghai) Bioscience Co., Ltd. Class A · SSE:688062US$1.02BUS$984.8Mn/a9.2×n/a9.5×−146.4%2.9×n/a
Median of the othersUS$1.08BUS$981.7M58.5×9.3×16.6×6.1×−137.6%0.4×1.47

Forecasts

8 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
41.13 USD · Analysts' mean
EPS, year to Dec 2026
-4.29 · 6 analysts
Revenue, year to Dec 2026
250K · 8 analysts

Team and board

Officers

OfficerRole
Tassos GianakakosCo-Founder, Chief Executive Officer and Chair
Brianne PuglisiChief Financial Officer
John MoriartyChief Legal Officer and Corporate Secretary
Michael BachnerExecutive Director, Corporate Communications
Andy PasternakChief Strategy Officer
Bob McDowellCo-Founder and Scientific Adviser
Diane HagertyChief Quality Officer
Donald MackenzieChief Technical Operations Officer
Emily FaucetteChief Communications Officer
Jay EdelbergCo-founder and Chief Medical Officer
Liz NguyenChief People Officer

Board

DirectorRole
Tassos GianakakosCo-Founder, Chief Executive Officer and Chair
David MeekerBoard of Directors
Kim PopovitsBoard of Directors
Kristin ReinkeBoard of Directors
Michael BachnerExecutive Director, Corporate Communications
Paul BernsBoard of Directors
Tim WalbertBoard of Directors

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−9.9%
Q2 2026Aug 11, 2026 · Before open+4.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck35 slidesSeptember 2026

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$460M raised · US$16 a share · J.P. Morgan Securities LLC +3
Dealers: J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC, TD Securities (USA) LLC
Jun 22, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Jun 17, 2026.

Price
US$16.00 a share
Shares offered
25,000,000 shares of common stock
Offering size
US$400 million
Underwriters' option
Up to 3,750,000 more shares
Listing
KARD on the Nasdaq Global Market
Underwriters
J.P. Morgan, Jefferies, Leerink Partners, TD Cowen · In the order on the cover
Shares delivered
On or about Jun 22, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceMar 26, 2026
Filed publiclyMay 26, 2026
Amended onceJun 11, 2026
Shares registered with an exchangeJun 15, 2026
Declared effective by the SECJun 17, 2026
Final prospectus, with the priceJun 18, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Jun 18, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue00
Research and development153.1M84.3M
Selling, general and administrative48.8M12.4M
Operating income-201.8M-96.7M
Depreciation and amortization5.85M346.0K
EBITDA-196.0M-96.3M
Income before tax-196.5M-88.7M
Income tax-4.51M
Net income-191.9M-88.7M
Earnings per share, basic-3.20-0.99

Balance sheet

LineFY2025FY2024
Cash and equivalents109.0M49.4M
Short-term investments226.5M0
Current assets345.4M50.3M
Total assets390.9M63.5M
Accounts payable7.99M3.86M
Current liabilities37.5M8.29M
Total debt13.8M
Total liabilities641.3M146.7M
Shareholders' equity-250.3M-83.2M
Shares outstanding60.0M89.3M

Cash flow

LineFY2025FY2024
Cash from operations-151.1M-18.8M
Capital spending-6.64M-36.4M
Free cash flow-157.7M-55.2M
Cash from investing-237.0M
Cash from financing447.8M105.0M
Change in cash59.7M49.8M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
8-K · Current reportNov 6, 2026Current reportSEC
4 · Change in ownershipOct 1, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 1, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 1, 2026Big-stake noticeSEC
8-K · Current reportSep 30, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
All 57 filings
FilingDateTypeFiled with
8-K · Current reportAug 11, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJun 29, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeJun 29, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeJun 25, 2026Big-stake noticeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
3/A · Initial statement of ownership, amendedJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
8-K · Current reportJun 23, 2026Current reportSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
424B4 · ProspectusJun 18, 2026Offer documentSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveJun 18, 2026Other filingsSEC
S-1MEF · Registration of more shares for the same offeringJun 17, 2026Offer documentSEC
3 · Initial statement of ownershipJun 17, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJun 17, 2026Offer documentSEC
CERT · Exchange's certificate of listingJun 17, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeJun 15, 2026Other filingsSEC
S-1/A · Registration statement, amendedJun 11, 2026Offer documentSEC
S-1 · Registration statementMay 26, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedMay 4, 2026Offer documentSEC
DRS · Draft registration statementMar 26, 2026Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Kardigan, Inc.’s releases · as of Nov 9, 2026

Common shares
93,597,398
Fully diluted
93,597,398

Fully diluted

LineSharesAs of
Common shares93,597,398Nov 9, 2026

Share count over time

CountShares
Nov 9, 202693,597,398

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Hrtg Gpe, LLC16.9M18.1%US$250MSep 30, 2026
ARCH Venture Management, LLC15M16.1%US$222MSep 30, 2026
Fidelity9.8M10.5%US$141MSep 30, 2026
Perceptive Advisors LLC8.2M8.8%US$121MSep 30, 2026
T. Rowe Price4.91M5.3%US$72.5MSep 30, 2026
Capital Group3.62M3.9%US$53.4MSep 30, 2026
BlackRock1.91M2.0%US$28.1MSep 30, 2026
JPMorgan1.76M1.9%US$25.8MSep 30, 2026
Vanguard1.63M1.7%US$24MSep 30, 2026
AllianceBernstein1.2M1.3%US$17.7MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Liberty Mutual Group Asset Management Inc.1.2M1.3%US$17.6MSep 30, 2026
Janus Henderson1.02M1.1%US$15MSep 30, 2026
Jennison Associates LLC927K0.99%US$13.7MSep 30, 2026
Paradigm Biocapital Advisors LP900K0.96%US$13.3MSep 30, 2026
Eventide Asset Management, LLC896K0.96%US$13.2MSep 30, 2026
Geode Capital757K0.81%US$11.2MSep 30, 2026
UBS734K0.78%US$10.8MSep 30, 2026
Sun Life637K0.68%US$9.39MSep 30, 2026
Deep Track Capital, LP600K0.64%US$8.85MSep 30, 2026
Goldman Sachs544K0.58%US$8.02MSep 30, 2026
Driehaus Capital Management LLC472K0.50%US$6.96MSep 30, 2026
State Street456K0.49%US$6.72MSep 30, 2026
BNY420K0.45%US$6.2MSep 30, 2026
Woodline Partners LP414K0.44%US$6.11MSep 30, 2026
Franklin Templeton400K0.43%US$5.65MSep 30, 2026
Catalio Capital Management, LP313K0.33%US$4.61MSep 30, 2026
Principal277K0.30%US$4.08MSep 30, 2026
Peregrine Capital Management LLC247K0.26%US$3.64MSep 30, 2026
Morgan Stanley245K0.26%US$3.61MSep 30, 2026
Schwab244K0.26%US$3.6MSep 30, 2026
Integral Health Asset Management, LLC225K0.24%US$3.32MSep 30, 2026
Northern Trust216K0.23%US$3.19MSep 30, 2026
Seven Grand Managers, LLC200K0.21%US$2.95MSep 30, 2026
Pier Capital, LLC186K0.20%US$2.74MSep 30, 2026
Bank of America166K0.18%US$2.44MSep 30, 2026
Ameriprise121K0.13%US$1.78MSep 30, 2026
Nomura82,2830.09%US$1.21MSep 30, 2026
Two Sigma65,8550.07%US$971KSep 30, 2026
TD60,4480.06%US$886KSep 30, 2026
Casdin Capital, LLC50,0000.05%US$738KSep 30, 2026
Ghisallo Capital Management LLC50,0000.05%US$738KSep 30, 2026
Nuveen47,7130.05%US$704KSep 30, 2026
Diadema Partners LP43,9720.05%US$649KSep 30, 2026
Sei Investments Co43,7040.05%US$645KSep 30, 2026
XTX Topco Ltd40,1090.04%US$592KSep 30, 2026
Millennium35,5280.04%US$524KSep 30, 2026
Alyeska Investment Group, L.P.30,0000.03%US$443KSep 30, 2026
ADAR1 Capital Management, LLC30,0000.03%US$443KSep 30, 2026
Rhumbline Advisers25,3670.03%US$374KSep 30, 2026
Shay Capital LLC25,0000.03%US$369KSep 30, 2026

This page holds 50 of 83 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
SMALLCAP World Fund Inc3.5M3.7%US$83.6MJun 30, 2026
Fidelity Contrafund1.09M1.2%US$26MJun 30, 2026
JPMorgan Small Cap Growth Fund824K0.88%US$19.6MJun 30, 2026
AB Small Cap Growth Portfolio742K0.79%US$17.7MJun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.737K0.79%US$17.6MJun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.633K0.68%US$15.1MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.445K0.48%US$10.6MJun 30, 2026
T. Rowe Price Institutional Small-Cap Stock Fund399K0.43%US$9.51MJun 30, 2026
Fidelity Blue Chip Growth Fund352K0.38%US$7.33MJul 31, 2026
Eventide Healthcare & Life Sciences Fund300K0.32%US$7.16MJun 30, 2026
All 49 holders
HolderSharesOf the companyValueAs of
JPMorgan Small Cap Blend Fund265K0.28%US$6.33MJun 30, 2026
Fidelity Contrafund K6227K0.24%US$5.43MJun 30, 2026
SmallCap Growth Fund I226K0.24%US$4.7MJul 31, 2026
BNY Mellon Small/Mid Cap Growth Fund182K0.19%US$4.35MJun 30, 2026
MFS New Discovery Series175K0.19%US$4.17MJun 30, 2026
VIP Contrafund Portfolio156K0.17%US$3.72MJun 30, 2026
Fidelity Advisor New Insights Fund145K0.16%US$3.47MJun 30, 2026
Franklin Biotechnology Discovery Fund145K0.15%US$3.02MJul 31, 2026
SmallCap Fund137K0.15%US$2.85MJul 31, 2026
Allspring Small Company Growth Fund98,9710.11%US$2.06MJul 31, 2026
SMALLCAP World Fund95,1000.10%US$2.27MJun 30, 2026
Vanguard Total Stock Market Index Fund94,5220.10%US$2.25MJun 30, 2026
Fidelity Series Opportunistic Insights Fund78,7000.08%US$1.88MJun 30, 2026
Optimum Small-Mid Cap Growth Fund74,2330.08%US$1.77MJun 30, 2026
Fidelity Blue Chip Growth K6 Fund73,2000.08%US$1.52MJul 31, 2026
Small-Cap Growth Portfolio66,6630.07%US$1.59MJun 30, 2026
Fidelity Series Blue Chip Growth Fund58,3000.06%US$1.21MJul 31, 2026
Blackstone Alternative Multi-Strategy Fund51,9570.06%US$1.24MJun 30, 2026
Small Cap Value Portfolio43,4190.05%US$1.04MJun 30, 2026
Carillon Chartwell Small Cap Fund43,3200.05%US$1.03MJun 30, 2026
Empower Small Cap Growth Fund39,6230.04%US$945KJun 30, 2026
AVIP AB Small Cap Portfolio39,3240.04%US$938KJun 30, 2026
Carillon Chartwell Small Cap Growth Fund33,6060.04%US$802KJun 30, 2026
Vanguard Extended Market Index Fund33,2540.04%US$793KJun 30, 2026
Driehaus Micro Cap Growth Fund21,4030.02%US$510KJun 30, 2026
Variable Portfolio - Partners Small Cap Growth Fund21,0160.02%US$501KJun 30, 2026
Penn Series Small Cap Value Fund19,5790.02%US$467KJun 30, 2026
AB Small Cap Growth Portfolio14,1820.02%US$338KJun 30, 2026
SmallCap Account12,5100.01%US$298KJun 30, 2026
Small Company Value Trust9,8470.01%US$235KJun 30, 2026
Large-Cap Growth Portfolio9,6050.01%US$229KJun 30, 2026
Dunham Small Cap Growth Fund8,629<0.01%US$180KJul 31, 2026
AVIP Fidelity Institutional AM Equity Growth Portfolio2,921<0.01%US$69,666Jun 30, 2026
T. Rowe Price Health Care ETF2,695<0.01%US$64,276Jun 30, 2026
Guardian Large Cap Fundamental Growth VIP Fund1,900<0.01%US$45,315Jun 30, 2026
Vanguard Balanced Index Fund1,615<0.01%US$38,518Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund1,435<0.01%US$34,225Jun 30, 2026
MFS Global Alternative Strategy Fund1,426<0.01%US$29,689Jul 31, 2026
T. Rowe Price Moderate Allocation Portfolio983<0.01%US$23,445Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Robert Nelsen
Director, 10% owner
Buy1,250,000USD 16.00US$20MJun 22, 2026
Paul L Berns
Director, 10% owner
Buy1,250,000USD 16.00US$20MJun 22, 2026
Hrtg Gpe, LLC
10% owner
Buy3,125,000USD 16.00US$50MJun 22, 2026

Big stakes

StakeStakeSharesDateFiling
Hrtg Gpe, LLC18.20%16.9MJun 22, 2026Schedule 13G
GIANAKAKOS ANASTASIOS11.10%10.5MJun 30, 2026Schedule 13G
FMR LLC10.30%9.22MJul 31, 2026Schedule 13G
Perceptive Advisors LLC8.80%8.25MSep 29, 2026Schedule 13D
Edelberg Jay5.20%4.88MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Timothy P. Walbert
Other companies: Latigo Biotherapeutics, Inc. (Chair, Board of Directors · Since at least Aug 6, 2026); Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); BioMarin Pharmaceutical Inc. (Director · Since at least Feb 24, 2025); Sagimet Biosciences Inc. - Series A (Director · Since at least Apr 1, 2024); Mirum Pharmaceuticals, Inc. (Director · Since at least Apr 5, 2023); Century Therapeutics, Inc. (Director · Since at least Oct 1, 2022); Aurinia Pharmaceuticals Inc (Director · Jan 1, 2021 – May 18, 2022 · Past); Assertio Holdings, Inc. (Director · May 20, 2020 – May 20, 2020 · Past); Exicure, Inc. (Director · Jul 22, 2019 – Jun 2, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Oct 12, 2015 – Feb 13, 2018 · Past); Egalet Corporation (Director · Mar 10, 2014 – May 20, 2020 · Past); Horizon Pharma PLC (Chairman, President and CEO, Director · Jul 28, 2011 – Mar 23, 2019 · Past); Raptor Pharmaceutical Corp (Director · Apr 11, 2011 – Mar 13, 2014 · Past); Idm Pharma Inc (President and CEO, Director · May 25, 2007 – Apr 3, 2008 · Past)
Board of Directors · Since at least Jun 17, 2026
Kristina Burow
Other companies: Metsera, Inc. (Director · Since at least Jan 30, 2025); Boundless Bio, Inc. (Director · Since at least Mar 27, 2024); Neumora Therapeutics, Inc. (Director · Since at least Sep 14, 2023); Scholar Rock Holding Corporation (Director · Since at least May 23, 2018); Metacrine Inc (Director · Sep 15, 2020 – May 24, 2021 · Past); Beam Therapeutics Inc. (Director · Feb 5, 2020 – Jun 6, 2023 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 21, 2020 · Past); Gossamer Bio, Inc. (Director · Feb 7, 2019 – Jun 8, 2023 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Receptos Inc (Director · Aug 25, 2015 – Aug 25, 2015 · Past)
Director · Since at least Jun 22, 2026
Keith Crandell
Other companies: Metsera, Inc. (Director · Since at least Nov 13, 2025); 908 Devices Inc. (Director · Since at least Dec 17, 2020); Twist Bioscience Corporation (Co-Founder and Managing Director · Since at least Oct 30, 2018); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 28, 2023 · Past); Quanterix Corporation (Director · Dec 6, 2017 – Apr 3, 2023 · Past); Adesto Technologies Corporation (Director · Oct 26, 2015 – Jun 4, 2019 · Past); Celebrate Express Inc (Director · Oct 19, 2006 – Aug 29, 2008 · Past)
Director · Since at least Jun 22, 2026
Kimberly Popovits
Other companies: Rhythm Pharmaceuticals, Inc. (Director · Since at least Apr 1, 2026); EXACT Sciences Corporation (Director · Since at least Jan 2, 2025); 10x Genomics, Inc. (Director · Since at least Mar 26, 2020); Kiniksa Pharmaceuticals International, plc (Director · Since at least May 23, 2018); Talis Biomedical Corp (Director · Feb 11, 2021 – Jun 9, 2023 · Past); MyoKardia Inc (Director · Mar 15, 2017 – Nov 17, 2020 · Past); Genomic Health Inc (President and CEO, Director · Nov 3, 2016 – Nov 8, 2019 · Past)
Director · Since at least Jun 17, 2026
David Meeker
Other companies: Pharvaris N.V. (Chair of the Board · Since at least Mar 18, 2026); Trevi Therapeutics, Inc. (Chairman · Since at least May 7, 2019); Rhythm Pharmaceuticals, Inc. (Chairman, President, and Chief Executive Officer · Since at least Oct 4, 2017); Turmeric Acquisition Corp (Director · Oct 15, 2020 – Oct 15, 2020 · Past); MyoKardia Inc (Director · Apr 17, 2017 – Nov 17, 2020 · Past); Savient Pharmaceuticals Inc (Director · Jan 7, 2013 – Jan 7, 2013 · Past)
Board of Directors · Since at least Jun 17, 2026
Steven Gillis
Other companies: Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 16, 2023 · Past); VBI Vaccines Inc. (Director · Jun 14, 2019 – Jul 27, 2023 · Past); Q32 Bio Inc. (Director · Jun 6, 2019 – Jun 14, 2023 · Past); Pulmatrix, Inc. (Director · May 16, 2019 – Aug 28, 2020 · Past)
Director · Since at least Jun 22, 2026
Paul L. Berns
Other companies: Metsera, Inc. (Director · Since at least Jan 30, 2025); Neumora Therapeutics, Inc. (See Remarks, Director · Since at least Sep 14, 2023); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Unity Biotechnology Inc (Director · Jun 24, 2021 – Jun 21, 2024 · Past); Jazz Pharmaceuticals plc (Director · Nov 2, 2020 – Aug 5, 2021 · Past)
Director · Since at least Jun 17, 2026
John Moriarty
Other companies: Avidity Biosciences, Inc (Chief Legal Officer · Since at least Aug 1, 2024); Olema Pharmaceuticals, Inc. (EVP, Ch. Legal Officer & Sec. · Sep 19, 2020 – Feb 1, 2023 · Past); Portola Pharmaceuticals Inc (EVP, General Counsel · Mar 12, 2018 – Jul 2, 2020 · Past); Alexion Pharmaceuticals Inc (EVP & General Counsel · Dec 10, 2012 – Feb 6, 2018 · Past)
Chief Legal Officer and Corporate Secretary · Since at least Jun 17, 2026
Bob McDowell
Other companies: MyoKardia Inc (Chief Scientific Officer · Oct 28, 2015 – Nov 17, 2020 · Past); Sunesis Pharmaceuticals Inc (Vice President, Research · Sep 11, 2007 – Sep 13, 2007 · Past)
Co-Founder and Scientific Adviser · Since at least Nov 5, 2026
Anastasios Gianakakos
Other companies: MyoKardia Inc (President and CEO, Director · Oct 28, 2015 – Nov 17, 2020 · Past)
President & CEO, Director · Since at least Jun 17, 2026
All 25 people
PersonSeat
Douglas E Giordano
Other companies: Cerevel Therapeutics Holdings Inc (Director · Jun 14, 2022 – Aug 1, 2024 · Past)
Director · Since at least Jun 17, 2026
Joseph Edelman
Other companies: Immatics N.V. (Director · Since at least Aug 26, 2026)
Director · Since at least Jun 17, 2026
Kim Popovits
Other companies: 10x Genomics, Inc. (Member · Since at least Jun 8, 2026)
Board of Directors · Since at least Jun 22, 2026
Robert Nelsen
Other companies: City Therapeutics, Inc. (Director · Since at least Oct 19, 2026)
Director · Since at least Jun 22, 2026
Andy PasternakChief Strategy Officer · Since at least Jun 22, 2026
Brianne JahnChief Financial Officer · Since at least Jun 17, 2026
Brianne PuglisiChief Financial Officer · Since at least Nov 5, 2026
Diane HagertyChief Quality Officer · Since at least Nov 5, 2026
Donald MackenzieChief Technical Operations Officer · Since at least Nov 5, 2026
Emily FaucetteChief Communications Officer · Since at least Nov 5, 2026
Jay EdelbergCo-founder and Chief Medical Officer · Since at least Jun 17, 2026
Kristin ReinkeBoard of Directors · Since at least Sep 30, 2026
Liz NguyenChief People Officer · Since at least Nov 4, 2026
Michael BachnerExecutive Director, Corporate Communications · Since at least Aug 11, 2026
Tassos GianakakosCo-Founder, Chief Executive Officer and Chair · Since at least Sep 30, 2026

Open People

Log in to ask 6ix AI your own questions about Kardigan, Inc.